TEL AVIV, Israel, June 26, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced a major milestone on the way to registration - the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate designed for the treatment of post-operative pain. In total, 428 patients have been enrolled at eight ...

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to ...

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-10 PAINREFORM LTD. CONDENSED BALANCE SHEETS (Unaudited) U.S. dollars in thousands As of As of December March 31, 31, Note 2024 2023 Assets Current assets: Cash a ...

Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 TEL AVIV, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2024. Ilan Hadar, Chief Executive Officer of PainReform, stated, " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5-F-6 Notes to Condensed Financial Statements F-7 - F-13 PAINREFORM LTD. CONDENSED BALANCE SHEETS U.S. dollars in thousands As of As of September December 30, 31, Note 2023 2022 Assets Current assets: ...

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-11 PAINREFORM LTD. CONDENSED BALANCE SHEETS U.S. dollars in thousands As of As of December June 30, 31, 2023 2022 Assets Current assets: Cash and cash equivalents ...

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-11 PAINREFORM LTD. CONDENSED BALANCE SHEETS U.S. dollars in thousands As of As of December March 31, 31, 2023 2022 Assets Current assets: Cash and cash equivalen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...